Gianfresco et al have published the first peer-reviewed analysis of COVID-19 infected, rheumatic disease patients entered into the Rheumatology Global Alliance registry; showing that a) rheumatic disease patient can be infected with COVID-19, b) that DMARD and biologic use has no apparent effect
Read Article
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read Article
The ACR has published the 2020 guidelines on the management of gout that includes strong recommendations favoring treat‐to‐target management and starting urate lowering therapy (ULT) for patients with frequent flares, radiographic damage or tophi due to gout.
Read Article
Dr. Jack Cush reviews the news, journal articles and new ACR COVID-19 guidelines from the past week on RheumNow.com.
On April 3rd, the National Institute for Health and Care Excellence (NICE) in the UK, published a rapid guideline for managing children and adults with rheumatological autoimmune, inflammatory and metabolic bone disorders during the COVID-19 pandemic, while protecting staff from infection.
Read Article
In the midst of a global pandemic of the 2019 Novel coronavirus acute respiratory disease (COVID-19), a small handful of Rheumatologists gathered on social media to collectively grapple with the impact of this virus on vulnerable populations with rheumatic disease.
A full-read, novel Viewpoint article published in the Annals of Rheumatic Disease (Huizinga TWJ, et al) spotlights a recent international meeting of big thinkers, scientific collaborators and industry dedicated to innovation in rheumatology.
Citing examples of developing disruptive
Read Article
The Annals of Rheumatic Disease reports that interleukin- 27 (IL-37) may play an important role in the pathogenesis of gout, paving the way for future therapy with recombinant IL-37 in gouty arthritis.
Activation of the inflammasome by monosodium urate crystals is thought to be
Read Article
Dr Jack Cush Reviews the news and journal articles from the past week on RheumNow.com
Read Article
Rheumatology has a comprehensive overview of methotrexate (MTX) and the risk of lung injury, MTX-related pneumonitis and interstitial lung disease (RA-ILD) with rheumatoid arthritis (RA). Past reports suggest the frequence of MTX-pneumonitis to be between 0.3 and 11.6%; recent
Read Article
There are numerous associations between hyperuricemia and cardiovascular disease (CVD). An analysis of the Swedish SCAPIS Pilot study shows that higher levels of serum urate (SU) are associated with an increase in coronary artery calcification score in men but not in women. SU is not associated
Read Article
Dr Jack Cush reviews the news and journal articles from the past week on RheumNow.com
Read Article
Both allopurinol and febuxostat (Uloric) were associated with an increased risk of hypersensitivity reactions among new users of these urate-lowering therapies, a large U.S. study found.
Compared with colchicine, the hazard ratios for hypersensitivity reactions on multivariate analyses
Read Article
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read Article
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for acute or chronic arthritis, headache, visceral pain, postoperative pain, etc but come with a small but significant risk of serious adverse effects, including hypertension, cardiovascular disease, kidney injury and GI
Read Article
Researchers from the Brigham and Women's Hospital have reported that adults with type 2 diabetes who were treated with SGLT2 inhibitors had a lower risk of gout compared to GLP1 agonist, suggesting that sodium–glucose cotransporter-2 inhibitors may reduce the risk for gout with type 2 diabetes
Read Article
The antidiabetic medication canagliflozin (Invokana) lowered serum urate and reduced the risk of gout flare in a post-hoc analysis of data from two large clinical trials.
In the CANVAS clinical trial program, which was funded by Janssen Research & Development and included more than
Read Article
Analysis of New Zealand hospitalized patients revals nine predictors of inpatient flare for people with comorbid gout.
This retrospective cohort study of hospitalised patients with comorbid gout included 625 hospitalised patients, 87 experienced inpatient gout flare.
There were 9
Read Article
Dr. Jack Cush recaps the news and journal reports from the past week on RheumNow.com.
Read Article
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
Read Article
Therapies targeting sUA accumulation or improving its excretion are widely used for treatment of symptoms and prevention of progression of gout for decades. Despite our best effort, there is still a significant amount of patients who remain symptomatic and/or experiences progressive
Read Article
Monday was another full day of sessions and studies here in Atlanta. Following is my roundup of day two.
The Safety of Methotrexate
Read Article
Gout is a systemic inflammatory disease with high potential for joint damage due to erosive changes and MSU deposits resulting in disability and chronic pain. Prompt diagnosis and effective treatment are key to better long term outcomes and decreased disability.
To
Read Article
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read Article
A Spanish prospective cohort of active, uncontrolled gout patients were followed and showed that failure to reach a target serum uric acid (sUA) level of 6 mg/dl (0.36 mmol/L) or less was associated with a 2-3 fold increase in mortality.
Researchers enrolled 1193 gout patients between
Read Article
